

11. A host cell comprising a nucleic acid molecule encoding the fusion protein of any one of claims 1 to 9.
12. A method of producing the fusion protein of any one of claims 1 to 9, comprising:
- 5 (1) culturing a host cell comprising a nucleic acid molecule encoding the fusion protein of any one of claims 1 to 9, under a condition that the fusion protein is produced; and
- (2) recovering the fusion protein produced by the host cell.
13. A pharmaceutical composition comprising the fusion protein of any one of claims 1 to 9 and a pharmaceutically acceptable carrier.
- 10 14. A pharmaceutical composition comprising a nucleic acid molecule encoding the fusion protein of any one of claims 1 to 9 and a pharmaceutically acceptable carrier.
- 15 15. A use of the fusion protein of any one of claims 1 to 9 in the manufacture of a medicament, wherein the medicament is used for treating or preventing a clinical condition selected from the group consisting of neovascularization, vascular permeability, edema and inflammation.
16. A use of the fusion protein of any one of claims 1 to 9 in the manufacture of a medicament, wherein the medicament is used for treating or preventing a clinical condition selected from the group consisting of choroidal neovascularization (CNV), wet age-related macular degeneration (AMD) and geographic atrophy.